Centene (CNC) Fundamentals 2026 — Revenue Analysis | SniperIQ
Centene (CNC) is a US-listed Healthcare company in Medical - Healthcare Plans with a market capitalization of
Centene (CNC) is a US-listed Healthcare company in Medical - Healthcare Plans with a market capitalization of
Centene (CNC) has a market capitalization of approximately
Centene's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Centene runs a net profit margin of -3.3%, a gross margin of 14.9%, and an operating margin of -3.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Centene reported revenue of
Centene does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Centene carries a debt-to-equity ratio of 0.76x and a current ratio of 1.12x, with a market beta of 1.08. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Centene (CNC) the key facts are: market cap
Get Centene's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.